Novel developments in thrombotic microangiopathies: Is there a common link between hemolytic uremic syndrome and thrombotic thrombocytic purpura?

Pediatric Nephrology

Volumn 26, Issue 11, 2011, Pages 1947-1956

  Zipfel, Peter F ^a,b   Wolf, Gunter ^c   John, Ulrike ^b   Kentouche, Karim ^b   Skerka, Christine ^a  

^a HANS KNÖLL INSTITUTE   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c Department of Internal Medicine   (Germany)

Author keywords

Complement; Hemolytic uremic syndrome; Thrombotic microangiopathies

Indexed keywords

COMPLEMENT COMPONENT C3B; COMPLEMENT FACTOR H; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; RITUXIMAB; STEROID; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ACUTE KIDNEY FAILURE; APOPTOSIS; AUTOIMMUNE DISEASE; CHICKENPOX; CLINICAL FEATURE; DIARRHEA; DISEASE ASSOCIATION; ESCHERICHIA COLI INFECTION; GENE MUTATION; GENETIC ANALYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; MOUTH INFECTION; NEPHRITIS; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOPHYSIOLOGY; PERTUSSIS; PLASMAPHERESIS; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SHIGELLOSIS; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE; THROMBOTIC THROMBOCYTOPENIC PURPURA; VASCULITIS;

HEMOLYTIC-UREMIC SYNDROME; HUMANS; PURPURA, THROMBOTIC THROMBOCYTOPENIC;

EID: 83155175392     PISSN: 0931041X     EISSN: 1432198X     Source Type: Journal    
DOI: 10.1007/s00467-011-1923-9     Document Type: Review

References (59)

1. Noris M, Remuzzi G (2005) Hemolytic uremic syndrome. J Am Soc Nephrol 16:1035-1050 (Pubitemid 41710314)
2. Zipfel PF, Heinen S, Skerka C (2010) Thrombotic microangiopathies: new insights and new challenges. Curr Opin Nephrol Hypertens 19:372-378
3. Gasser CGE, Steck (1955) Hemolytic-uremic syndromes: bilateral necrosis of the renal cortex in acute acquired hemolytic anemia. Schweiz Med Wochenschr 85:905-909
4. Zipfel PF, Mache C, Müller D, Licht C, Wigger M, Skerka C. European DEAP-HUS Study Group (2010) DEAP-HUS: deficiency of CFHR plasma proteins and autoantibody-positive form of hemolytic uremic syndrome. Pediatr Nephrol 25:2009-2019
5. Copelovitch L, Kaplan BS (2010) Streptococcus pneumoniaeassociated hemolytic uremic syndrome: classification and the emergence of serotype 19A. Pediatrics 125:e174-e182
6. Leopold SR, Magrini V, Holt NJ, Shaikh N, Mardis ER, Cagno J, Ogura Y, Iguchi A, Hayashi T, Mellmann A, Karch H, Besser TE, Sawyer SA, Whittam TS, Tarr PI (2009) A precise reconstruction of the emergence and constrained radiations of Escherichia coli O157 portrayed by backbone concatenomic analysis. Proc Natl Acad Sci USA 106(21):8713-8718
7. Moake J (2009) Thrombotic thrombocytopenia purpura (TTP) and other thrombotic microangiopathies. Best Pract Res Clin Haematol 22:567-576
8. Ludwig K, Bitzan M, Bobrowski C, Müller-Wiefel DE (2002) Escherichia coliO157 fails to induce a long-lasting lipopolysaccharide- specific, measurable humoral immune response in children with hemolytic-uremic syndrome. J Infect Dis 186:566-569 (Pubitemid 34876269)
9. Johannes L, Römer W (2010) Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol 8:105-116
10. Karch H, Friedrich AW, Gerber A, Zimmerhackl LB, Schmidt MA, Bielaszewska M (2006) New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. Semin Thromb Hemost 32:105-112
11. Orth D, Khan AB, Naim A, Grif K, Brockmeyer J, Karch H, Joannidis M, Clark SJ, Day AJ, Fidanzi S, Stoiber H, Dierich MP, Zimmerhackl LB, Wurzner R (2009) Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 182:6394-6400
12. Chaturvedi S, Licht C, Langlois V (2010) Hemolytic uremic syndrome caused by Bordetella pertussis infection. Pediatr Nephrol 25:1361-1364
13. Kwon T, Belot A, Ranchin B, Baudouin V, Fremeaux-Bacchi V, Dragon-Durey MA, Cochat P, Loirat C (2009) Varicella as a trigger of atypical haemolytic uraemic syndrome associated with complement dysfunction: two cases. Nephrol Dial Transplant 24:2752-2754
14. Richards A, Buddles MR, Donne RL, Kaplan BS, Kirk E, Venning MC, Tielemans CL, Goodship JA, Goodship TH (2001) Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, adomain important for host cell recognition. Am J Hum Genet 68:485-490 (Pubitemid 32147817)
15. Saunders RE, Abarrategui-Garrido C, Fremeaux-Bacchi V, Goicoechea de Jorge E, Goodship TH, Lopez Trascasa M, Noris M, Ponce Castro IM, Remuzzi G, Rodriguez de Cordoba S, Sanchez-Corral P, Skerka C, Zipfel PF, Perkins SJ (2007) The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Hum Mutat 28:222-234
16. Jozsi M, Zipfel PF (2008) Factor H family proteins and human diseases. Trends Immunol 29:380-387
17. Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9:729-740
18. Delvaeye M, Noris M, De Vriese A, Esmon CT, Esmon NL, Ferrell G, Del-Favero J, Plaisance S, Claes B, Lambrechts D, Zoja C, Remuzzi G, Conway EM (2009) Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Eng J Med 361:345-357
19. Hanly AM, Winter DC (2007) The role of thrombomodulin in malignancy. Semin Thromb Hemost 33:673-679 (Pubitemid 350157011)
20. Coppo P, Schwarzinger M, Buffet M, Wynckel A, Clabault K, Presne C, Poullin P, Malot S, Vanhille P, Azoulay E, Galicier L, Lemiale V, Mira JP, Ridel C, Rondeau E, Pourrat J, Girault S, Bordessoule D, Saheb S, Ramakers M, Hamidou M, Vernant JP, Guidet B, Wolf M, Veyradier A; French Reference Center for Thrombotic Microangiopathies (2010) Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience. PLoS ONE 5(4):e10208
21. Skerka C, Jozsi M, Zipfel PF, Dragon-Durey MA, Fremeaux- Bacchi V (2009) Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 101:227-232
22. Jozsi M, Strobel S, Dahse HM, Liu WS, Hoyer PF, Oppermann M, Skerka C, Zipfel PF (2007) Anti factor H autoantibodies block Cterminal recognition function of factor H in hemolytic uremic syndrome. Blood 110:1516-1518 (Pubitemid 47443967)
23. Dragon-Durey MA, Blanc C, Marliot F, Loirat C, Blouin J, Sautes-Fridman C, Fridman WH, Fremeaux-Bacchi V (2009) The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J Med Genet 46:447-450
24. Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, Hoppe B, Routledge D, Strain L, Hughes AE, Goodship JA, Licht C, Goodship TH, Skerka C (2007) Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet 3:e41
25. Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, Schmidt CQ, Staniforth SJ, Holmes LV, Ward R, Morgan L, Goodship TH, Marchbank KJ (2009) Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 115:379-387
26. Waters AM, Pappworth I, Marchbank K, Bockenhauer D, Tullus K, Pickering MC, Strain L, Sebire N, Shroff R, Marks SD, Goodship TH, Rees L (2009) Successful renal transplantation in factor H autoantibody associated HUS with CFHR1 and 3 deficiency and CFH variant G2850T. Am J Transplant 10:168-172
27. Skerka C, Licht C, Mengel M, Uzonyi B, Strobel S, Zipfel PF, Jozsi M (2009) Autoimmune forms of thrombotic micorangiopathy and membranoproliferative glomerulonephritis: indications for a disease spectrum and common pathogenic principles. Mol Immunol 46:2801-2807
28. Fremeaux-Bacchi V, Miller EC, Liszewski MK, Strain L, Blouin J, Brown AL, Moghal N, Kaplan BS, Weiss RA, Lhotta K, Kapur G, Mattoo T, Nivet H, Wong W, Gie S, Hurault de Ligny B, Fischbach M, Gupta R, Hauhart R, Meunier V, Loirat C, Dragon-Durey MA, Fridman WH, Janssen BJ, Goodship TH, Atkinson JP (2008) Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 112:4948-4952
29. Fakhouri F, Frémeaux-Bacchi V, Noël LH, Cook HT, Pickering MC (2010) C3 glomerulopathy: a new classification. Nat Rev Nephrol 6(8):494-499
30. Pickering MC, Cook HT (2008) Translational mini-review series on complement factor H: renal diseases associated with complement factor H: novel insights from humans and animals. Clin Exp Immunol 151(2):210-230
31. Chen M, Daha MR, Kallenberg CG (2010) The complement system in systemic autoimmune disease. J Autoimmun 34:276-286
32. Masilamani M, Nowack R, Witte T, Schlesier M, Warnatz K, Glocker MO, Peter HH, Illges H (2004) Reduction of soluble complement receptor 2/CD21 in systemic lupus erythromatosus and Sjogren's syndrome but not juvenile arthritis. Scand J Immunol 60:625-630 (Pubitemid 39665108)
33. Carroll MC (2004) A protective role for innate immunity in systemic lupus erythematosus. Nat Rev Immunol 4:825-831 (Pubitemid 39336298)
34. Peng Y, Martin DA, Kenkel J, Zhang K, Ogden CA, Elkon KB (2007) Innate and adaptive immune response to apoptotic cells. J Autoimmun 29(4):303-309 (Pubitemid 47633145)
35. Gruppo RA, Rother RP (2009) Eculizumab for congenital atypical hemolytic-uremic syndrome. N Eng J Med 360:544-546
36. Nurnberger J, Philipp T, Witzke O, Opazo Saez A, Vester U, Baba HA, Kribben A, Zimmerhackl LB, Janecke AR, Nagel M, Kirschfink M (2009) Eculizumab for atypical hemolytic-uremic syndrome. N Eng J Med 360:542-544
37. Hillmen P (2008) The role of complement inhibition in PNH. Hematology Am Soc Hematol Educ Program2008:116-123
38. Mache CJ, Acham-Roschitz B, Fremeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E (2009) Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1312-1316
39. Thurman JM, Marians R, Emlen W, Wood S, Smith C, Akana H, Holers VM, Lesser M, Kline M, Hoffman C, Christen E, Trachtman H (2009) Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 4:1920-1924
40. Banda NK, Levitt B, Glogowska MJ, Thurman JM, Takahashi K, Stahl GL, Tomlinson S, Arend WP, Holers VM (2010) Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 183:5928-5937
41. Tsai HM (2010) Pathophysiology of thrombotic thrombocytopenic purpura. Int J Hematol 91:1-19
42. Moschcowitz E (1924) Proc NY Pathol Soc 24:21-24
43. Moake JL (1991) TTP-desperation, empiricism, progress. N Engl J Med 325(6):426-428
44. De Groot R, Lane DA (2008) Shear tango: dance of the ADAMTS13/VWF complex. Blood 112:1548-1549
45. Furlan M, Robles R, Lämmle B (1996) Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223-4234 (Pubitemid 26152266)
46. Tsai HM, Lian EC (1998) Antibodies to von Willebrand factorcleaving protease in acute thrombotic thrombocytopenic purpura. N Engl J Med 339:1585-1594 (Pubitemid 28536133)
47. Turner NA, Nolasco L, Ruggeri ZM, Moake JL (2009) Endothelial cell ADAMTS-13 and VWF: production, release, and VWF string cleavage. Blood 114:5102-5111
48. Bianchi V, Robles R, Alberio L, Furlan M, Lämmle B (2002) Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura. Blood 100:710-713 (Pubitemid 34761143)
49. Pos W, Crawley JT, Fijnheer R, Voorberg J, Lane DA, Luken BM (2010) An autoantibody epitope comprising residues R660, Y661 and Y665 in the ADAMTS13 spacer domain identifies a binding site for the A2 domain of VWF. Blood 115:1640-1649
50. Raife TJ, Cao W, Atkinson BS, Bedell B, Montgomery RR, Lentz SR, Johnson GF, Zheng XL (2009) Leukocyte proteases cleave von Willebrand factor at or near the ADAMTS13 cleavage site. Blood 114:1666-1674
51. Illner N, Wolf G (2010) Rituximab as effective therapy in very severe thrombotic thrombocytopenic purpura (TTP). Dtsch Med Wochenschr 135:71-74
52. Bresin E, Gastoldi S, Daina E, Belotti D, Pogliani E, Perseghin P, Scalzulli PR, Paolini R, Marceno R, Remuzzi G, Galbusera M (2009) Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thromb Haemost 101:233-238
53. McDonald V, Manns K, Mackie IJ, Machin SJ, Scully MA (2010) Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost 8:1201-1208
54. Mayr FB, Knöbl P, Jilma B, Siller-Matula JM,Wagner PG, Schaub RG, Gilbert JC, Jilma-Stohlawetz P (2010) The aptamer ARC1779 blocks von Willebrand factor-dependent platelet function in patients with thrombotic thrombocytopenic purpura ex vivo. Transfusion 50:1079-1087
55. Derzsy Z, Prohászka Z, Rigó J Jr, Füst G, Molvarec A (2010) Activation of the complement system in normal pregnancy and preeclampsia. Mol Immunol 47:1500-1506
56. Manea M, Tati R, Karlsson J, Bekassy ZD, Karpman D (2010) Biologically active ADAMTS13 is expressed in renal tubularepithelial cells. Pediatr Nephrol 25:87-96
57. Ståhl AL, Vaziri-Sani F, Heinen S, Kristoffersson AC, Gydell KH, Raafat R, Gutierrez A, Beringer O, Zipfel PF, Karpman D (2008) Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation. Blood 111:5307-5315
58. Licht C, Pluthero FG, Li L, Christensen H, Habbig S, Hoppe B, Geary DF, Zipfel PF, Kahr WH (2009) Platelet-associated complement factor H in healthy persons and patients with atypical HUS. Blood 114:4538-4545
59. Ferrari S, Mudde GC, Rieger M, Veyradier A, Kremer Hovinga JA, Scheiflinger F (2009) IgG subclass distribution of anti-ADAMTS13 antibodies in patients with acquired thrombotic thrombocytopenic purpura. J Thromb Haemost 7:1703-1710